Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial

Abstract Androgen deprivation therapy (ADT) used for prostate cancer (PCa) management is associated with metabolic and anthropometric toxicity. Metformin given concurrent to ADT is hypothesized to counteract these changes. This planned interim analysis reports the gastrointestinal and genitourinary...

Full description

Saved in:

Bibliographic Details
Main Authors:	Julian O. Kim, Megan O. McDonald, Aldrich Ong, Rashmi Koul, Arbind Dubey, William Hunter, Shahida Ahmed, Harvey Quon, Don Yee, Matthew Parliament, Gokulan Sivananthan, Brita Danielson, Lindsay Rowe, Sunita Ghosh, Nawaid Usmani
Format:	article
Language:	EN
Published:	BMC 2021
Subjects:	Metformin Prostate cancer Gastrointestinal toxicity Genitourinary toxicity Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/8e04f6c57db3446ca965c661d060cba7
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial

Similar Items